0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover258.75%IV-89.87%PremiumAug 16, 2024Expiry Date3.55Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7735Delta0.1270Gamma1.05Leverage Ratio-0.0172Theta-0.0029Rho-0.81Eff Leverage0.0028Vega
Poseida Therapeutics Stock Discussion
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
No comment yet